Empowering Patients: Navigating the Progression Risks of Actinic Keratosis and Optimizing Treatment Selection


In this episode of MEDcast, expert dermatologists discuss actinic keratosis, a premalignant skin condition. They are sharing their thoughts on the importance of early diagnosis and treatment and are delving into treatment options, in particular photodynamic treatments.

To watch the video series component of this episode, click here.

00:00 Introduction

00:55 Educating your patients with actinic keratosis on progression to squamous cell carcinoma and field cancerization.

06:15 The different treatments options available for actinic keratosis.

07:42 Evidence based treatment selection in actinic keratosis; sequencing and combining therapies

10:48 Photodynamictherapy for treatment of actinic keratosis

14:38 Comparing blue versus red light

20:30 Comparison studies on photodynamic therapy used with various used in combination with formulations of photosensitizing agent

24:10 Optimizing the use of photodynamic therapy for extremities in patients with actinic keratosis

27:50 The efficacy, safety and adherence of the different treatment modalities based in actinic keratosis

31:45 Summary

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.